Theravance Biopharma (TBPH)
NASDAQ:TBPH
Total Valuation
Theravance Biopharma has a market cap or net worth of $824.92M. The enterprise value is $732.61M.
Market Cap$824.92M
Enterprise Value$732.61M
Share Statistics
Theravance Biopharma has 51,492,924 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,492,924
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Theravance Biopharma’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -2.37%.
Return on Equity (ROE)0.36
Return on Assets (ROA)0.22
Return on Invested Capital (ROIC)-2.37%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee1.11M
Profits Per Employee1.09M
Employee Count97
Asset Turnover0.22
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Theravance Biopharma is 8.9. Theravance Biopharma’s PEG ratio is -0.03.
PE Ratio8.9
PS Ratio8.76
PB Ratio3.17
Price to Fair Value3.17
Price to FCF3.95
Price to Operating Cash Flow3.42
PEG Ratio-0.03
Income Statement
In the last 12 months, Theravance Biopharma had revenue of 107.46M and earned 105.89M in profits. Earnings per share was 2.10.
Revenue107.46M
Gross Profit101.95M
Operating Income-13.25M
Pretax Income129.25M
Net Income105.89M
EBITDA-7.73M
Earnings Per Share (EPS)2.10
Cash Flow
In the last 12 months, operating cash flow was 238.54M and capital expenditures -42.00K, giving a free cash flow of 238.50M billion.
Operating Cash Flow238.54M
Free Cash Flow238.50M
Free Cash Flow per Share4.63
Dividends & Yields
Theravance Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change90.49%
50-Day Moving Average17.15
200-Day Moving Average15.39
Relative Strength Index (RSI)54.26
Average Volume (3m)684.19K
Important Dates
Theravance Biopharma upcoming earnings date is May 6, 2026, Before Open (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Theravance Biopharma as a current ratio of 10.93, with Debt / Equity ratio of 25.44%
Current Ratio10.93
Quick Ratio10.93
Debt to Market Cap0.05
Net Debt to EBITDA11.94
Interest Coverage Ratio-5.38
Taxes
In the past 12 months, Theravance Biopharma has paid 23.35M in taxes.
Income Tax23.35M
Effective Tax Rate0.18
Enterprise Valuation
Theravance Biopharma EV to EBITDA ratio is -109.83, with an EV/FCF ratio of 3.56.
EV to Sales7.90
EV to EBITDA-109.83
EV to Free Cash Flow3.56
EV to Operating Cash Flow3.56
Balance Sheet
Theravance Biopharma has $315.36M in cash and marketable securities with $75.50M in debt, giving a net cash position of $239.86M billion.
Cash & Marketable Securities$315.36M
Total Debt$75.50M
Net Cash$239.86M
Net Cash Per Share$4.66
Tangible Book Value Per Share$5.90
Margins
Gross margin is 94.87%, with operating margin of -12.33%, and net profit margin of 98.54%.
Gross Margin94.87%
Operating Margin-12.33%
Pretax Margin120.27%
Net Profit Margin98.54%
EBITDA Margin-7.19%
EBIT Margin-12.33%
Analyst Forecast
The average price target for Theravance Biopharma is $16.11, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.11
Price Target Upside0.56% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast27.12%
EPS Growth Forecast―